NASDAQ:NKTR

Nektar Therapeutics News Headlines

$19.73
-0.37 (-1.84 %)
(As of 05/10/2021 12:00 AM ET)
Add
Compare
Today's Range
$19.56
$20.25
50-Day Range
$18.52
$22.38
52-Week Range
$15.40
$26.75
Volume975,284 shs
Average Volume1.19 million shs
Market Capitalization$3.60 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.76

Headlines

Nektar Therapeutics (NASDAQ NKTR) News Headlines Today

SourceHeadline
Nektar Therapeutics (NKTR) Buy Rating Reaffirmed at MizuhoNektar Therapeutics' (NKTR) Buy Rating Reaffirmed at Mizuho
marketbeat.com - May 7 at 7:33 AM
Nektar Therapeutics (NASDAQ:NKTR) Price Target Cut to $20.00 by Analysts at SVB LeerinkNektar Therapeutics (NASDAQ:NKTR) Price Target Cut to $20.00 by Analysts at SVB Leerink
americanbankingnews.com - May 10 at 2:02 PM
Nektar Therapeutics (NASDAQ:NKTR) Just Reported And Analysts Have Been Cutting Their EstimatesNektar Therapeutics (NASDAQ:NKTR) Just Reported And Analysts Have Been Cutting Their Estimates
nasdaq.com - May 10 at 9:51 AM
Nektar (NKTR) Moves 8.5% Higher: Will This Strength Last?Nektar (NKTR) Moves 8.5% Higher: Will This Strength Last?
finance.yahoo.com - May 10 at 9:51 AM
Nektar Therapeutics (NASDAQ:NKTR) Releases Quarterly  Earnings Results, Beats Estimates By $0.04 EPSNektar Therapeutics (NASDAQ:NKTR) Releases Quarterly Earnings Results, Beats Estimates By $0.04 EPS
americanbankingnews.com - May 9 at 5:12 PM
Nektar Therapeutics (NASDAQ:NKTR) Given "Buy" Rating at MizuhoNektar Therapeutics (NASDAQ:NKTR) Given "Buy" Rating at Mizuho
americanbankingnews.com - May 7 at 8:22 AM
Nektar Therapeutics (NKTR) Q1 2021 Earnings Call TranscriptNektar Therapeutics (NKTR) Q1 2021 Earnings Call Transcript
fool.com - May 7 at 3:46 AM
June 25th Options Now Available For Nektar Therapeutics (NKTR)June 25th Options Now Available For Nektar Therapeutics (NKTR)
nasdaq.com - May 6 at 10:10 PM
Nektar Therapeutics (NKTR) Reports Q1 Loss, Lags Revenue EstimatesNektar Therapeutics (NKTR) Reports Q1 Loss, Lags Revenue Estimates
finance.yahoo.com - May 6 at 10:10 PM
Nektar Therapeutics (NASDAQ:NKTR) Expected to Announce Earnings of -$0.74 Per ShareNektar Therapeutics (NASDAQ:NKTR) Expected to Announce Earnings of -$0.74 Per Share
americanbankingnews.com - May 3 at 10:22 AM
Would Shareholders Who Purchased Nektar Therapeutics (NASDAQ:NKTR) Stock Three Years Be Happy With The Share price Today?Would Shareholders Who Purchased Nektar Therapeutics' (NASDAQ:NKTR) Stock Three Years Be Happy With The Share price Today?
nasdaq.com - April 28 at 12:57 PM
Nektar to Announce Financial Results for the...Nektar to Announce Financial Results for the...
benzinga.com - April 27 at 8:15 PM
NKTR Aug 2021 23.000 callNKTR Aug 2021 23.000 call
ca.finance.yahoo.com - April 25 at 10:40 AM
Nektar Therapeutics (NASDAQ:NKTR) Receives Average Rating of "Hold" from AnalystsNektar Therapeutics (NASDAQ:NKTR) Receives Average Rating of "Hold" from Analysts
americanbankingnews.com - April 17 at 3:12 AM
First Week of June 18th Options Trading For Nektar Therapeutics (NKTR)First Week of June 18th Options Trading For Nektar Therapeutics (NKTR)
nasdaq.com - April 16 at 7:20 PM
Nektar (NKTR) Down 10.9% Since Last Earnings Report: Can It Rebound?Nektar (NKTR) Down 10.9% Since Last Earnings Report: Can It Rebound?
finance.yahoo.com - March 27 at 12:28 PM
NKTR Mar 2021 19.500 putNKTR Mar 2021 19.500 put
uk.finance.yahoo.com - March 26 at 3:54 PM
NKTR Mar 2021 20.000 callNKTR Mar 2021 20.000 call
uk.finance.yahoo.com - March 26 at 3:54 PM
Interesting NKTR Put Options For May 7thInteresting NKTR Put Options For May 7th
nasdaq.com - March 25 at 7:38 PM
Interesting NKTR Put And Call Options For November 19thInteresting NKTR Put And Call Options For November 19th
nasdaq.com - March 19 at 1:52 PM
NKTR Jan 2022 22.000 putNKTR Jan 2022 22.000 put
sg.finance.yahoo.com - March 19 at 8:51 AM
NKTR Mar 2021 22.000 putNKTR Mar 2021 22.000 put
uk.finance.yahoo.com - March 14 at 7:34 AM
NKTR Mar 2021 13.500 putNKTR Mar 2021 13.500 put
uk.finance.yahoo.com - March 13 at 11:29 PM
NKTR Mar 2021 20.500 putNKTR Mar 2021 20.500 put
au.finance.yahoo.com - March 12 at 7:26 PM
NKTR Mar 2021 19.000 callNKTR Mar 2021 19.000 call
au.finance.yahoo.com - March 12 at 7:26 PM
NKTR Mar 2021 24.500 putNKTR Mar 2021 24.500 put
au.finance.yahoo.com - March 12 at 2:26 PM
NKTR April 30th Options Begin TradingNKTR April 30th Options Begin Trading
nasdaq.com - March 11 at 2:23 PM
Nektar Therapeutics Stock Likely To See Higher LevelsNektar Therapeutics Stock Likely To See Higher Levels
nasdaq.com - March 3 at 6:59 PM
Nektar Therapeutics (NKTR) CEO Howard Robin on Q4 2020 Results - Earnings Call TranscriptNektar Therapeutics (NKTR) CEO Howard Robin on Q4 2020 Results - Earnings Call Transcript
seekingalpha.com - February 27 at 10:32 PM
Need To Know: The Consensus Just Cut Its Nektar Therapeutics (NASDAQ:NKTR) Estimates For 2021Need To Know: The Consensus Just Cut Its Nektar Therapeutics (NASDAQ:NKTR) Estimates For 2021
finance.yahoo.com - February 26 at 3:40 PM
Nektar (NKTR) Q4 Earnings and Revenues Top, Pipeline On TrackNektar (NKTR) Q4 Earnings and Revenues Top, Pipeline On Track
nasdaq.com - February 26 at 10:15 AM
Nektar Therapeutics (NKTR) Q4 2020 Earnings Call TranscriptNektar Therapeutics (NKTR) Q4 2020 Earnings Call Transcript
fool.com - February 26 at 1:14 AM
Nektar Therapeutics: Q4 Earnings InsightsNektar Therapeutics: Q4 Earnings Insights
finance.yahoo.com - February 25 at 11:46 PM
Is a Surprise Coming for Nektar (NKTR) This Earnings Season?Is a Surprise Coming for Nektar (NKTR) This Earnings Season?
msn.com - February 24 at 12:43 PM
Will Nektar Therapeutics (NKTR) Report Negative Q4 Earnings? What You Should KnowWill Nektar Therapeutics (NKTR) Report Negative Q4 Earnings? What You Should Know
nasdaq.com - February 18 at 6:37 PM
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2020 on Thursday, February 25, 2021, After Close of U.S.-Based Financial MarketsNektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2020 on Thursday, February 25, 2021, After Close of U.S.-Based Financial Markets
finance.yahoo.com - February 18 at 6:37 PM
Even A Novice Can Spot Nektar Therapeutics PotentialEven A Novice Can Spot Nektar Therapeutics' Potential
seekingalpha.com - February 18 at 1:36 PM
Nektar (NKTR) Teams Up With Merck for Head & Neck Cancer StudyNektar (NKTR) Teams Up With Merck for Head & Neck Cancer Study
msn.com - February 18 at 1:36 PM
NKTR Teams Up With MRK, Pfizer Initiates Multiple Myeloma Trial, PCSA On WatchNKTR Teams Up With MRK, Pfizer Initiates Multiple Myeloma Trial, PCSA On Watch
nasdaq.com - February 18 at 12:17 AM
Stock Alert: Nektar Therapeutics Up 13% On Collaboration With MerckStock Alert: Nektar Therapeutics Up 13% On Collaboration With Merck
nasdaq.com - February 17 at 7:17 PM
S.F. biotech racks up 2 big cancer-fighting deals with giant Merck, East Bay drugmakerS.F. biotech racks up 2 big cancer-fighting deals with giant Merck, East Bay drugmaker
bizjournals.com - February 17 at 2:16 PM
Nektar Collaborates With SFJ Pharma For Bempegaldesleukin In Head And Neck CancerNektar Collaborates With SFJ Pharma For Bempegaldesleukin In Head And Neck Cancer
markets.businessinsider.com - February 17 at 9:15 AM
Nektar Announces Collaboration with SFJ Pharmaceuticals® for Bempegaldesleukin in Head and Neck CancerNektar Announces Collaboration with SFJ Pharmaceuticals® for Bempegaldesleukin in Head and Neck Cancer
finance.yahoo.com - February 17 at 9:15 AM
Nektar Announces Agreement for Phase 2/3 Study of IL-2 Pathway Agonist, Bempegaldesleukin, in Combination with Mercks KEYTRUDA® (pembrolizumab) in Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN)Nektar Announces Agreement for Phase 2/3 Study of IL-2 Pathway Agonist, Bempegaldesleukin, in Combination with Merck's KEYTRUDA® (pembrolizumab) in Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN)
finance.yahoo.com - February 17 at 9:15 AM
Investors Who Bought Nektar Therapeutics (NASDAQ:NKTR) Shares Five Years Ago Are Now Up 75%Investors Who Bought Nektar Therapeutics (NASDAQ:NKTR) Shares Five Years Ago Are Now Up 75%
finance.yahoo.com - February 8 at 5:39 PM
NKTR Feb 2021 22.000 putNKTR Feb 2021 22.000 put
uk.finance.yahoo.com - February 5 at 10:55 PM
NKTR Feb 2021 18.500 putNKTR Feb 2021 18.500 put
uk.finance.yahoo.com - February 5 at 5:54 PM
NKTR Feb 2021 22.000 callNKTR Feb 2021 22.000 call
uk.finance.yahoo.com - February 5 at 5:54 PM
Nektar Therapeutics Breaks Below 200-Day Moving Average - Notable for NKTRNektar Therapeutics Breaks Below 200-Day Moving Average - Notable for NKTR
nasdaq.com - February 2 at 7:37 PM
3 Stocks Wall Street Thinks Will Soar 50% or More in 20213 Stocks Wall Street Thinks Will Soar 50% or More in 2021
finance.yahoo.com - February 1 at 8:05 AM
NKTR Jan 2021 16.500 callNKTR Jan 2021 16.500 call
uk.finance.yahoo.com - January 23 at 7:00 PM
This page was last updated on 5/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.